abstract |
The present invention provides therapeutic formulations for solutions of Δ9-tetrahydrocannabinol to be delivered by metered dose inhalers (100), (102). The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of Δ9-tetrahydrocannabinol for the treatment of various medical conditions, such as nausea, and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders. |